71 related articles for article (PubMed ID: 22402361)
1. [Population pharmacokinetics applied to optimising cisplatin doses in cancer patients].
Ramón-López A; Escudero-Ortiz V; Carbonell V; Pérez-Ruixo JJ; Valenzuela B
Farm Hosp; 2012; 36(5):392-402. PubMed ID: 22402361
[TBL] [Abstract][Full Text] [Related]
2. [Populational pharmacokinetics of doxorubicin applied to personalised its dosing in cancer patients].
Escudero-Ortiz V; Ramón-López A; Duart MA; Pérez-Ruixo JJ; Valenzuela B
Farm Hosp; 2012; 36(4):282-91. PubMed ID: 22129650
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics of PM00104 (Zalypsis(®)) in cancer patients.
Pérez-Ruixo C; Valenzuela B; Fernández Teruel C; González-Sales M; Miguel-Lillo B; Soto-Matos A; Pérez-Ruixo JJ
Cancer Chemother Pharmacol; 2012 Jan; 69(1):15-24. PubMed ID: 21590449
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of platinum after oral or intravenous cisplatin: a phase 1 study in 32 adult patients.
Urien S; Brain E; Bugat R; Pivot X; Lochon I; Van ML; Vauzelle F; Lokiec F
Cancer Chemother Pharmacol; 2005 Jan; 55(1):55-60. PubMed ID: 15258698
[TBL] [Abstract][Full Text] [Related]
5. [Population pharmacokinetics of gemcitabine applied to personalize the dosage used in cancer patients].
Ramón-López A; Escudero-Ortiz V; Duart-Duart MJ; Pérez-Ruixo JJ; Valenzuela B
Farm Hosp; 2012; 36(4):194-206. PubMed ID: 22078546
[TBL] [Abstract][Full Text] [Related]
6. Circadian variability of pharmacokinetics of cisplatin in patients with non-small-cell lung carcinoma: analysis with the NONMEM program.
Chen R; Li J; Hu WW; Wang ML; Zou SL; Miao LY
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1111-23. PubMed ID: 24061864
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of cisplatin in adult cancer patients.
de Jongh FE; Gallo JM; Shen M; Verweij J; Sparreboom A
Cancer Chemother Pharmacol; 2004 Aug; 54(2):105-12. PubMed ID: 15127229
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic variability of nimodipine disposition after single and multiple oral dosing to hypertensive renal failure patients: parametric and nonparametric population analysis.
Terziivanov D; Atanasova I; Dimitrova V; Robeva R; Unger S; Mück W
Int J Clin Pharmacol Ther; 1999 Aug; 37(8):404-12. PubMed ID: 10475143
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics of cisplatin in patients with advanced ovarian cancer during intraperitoneal hyperthermia chemotherapy.
Panteix G; Beaujard A; Garbit F; Chaduiron-Faye C; Guillaumont M; Gilly F; Baltassat P; Bressolle F
Anticancer Res; 2002; 22(2B):1329-36. PubMed ID: 12168946
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors.
Guo F; Letrent SP; Sharma A
Cancer Chemother Pharmacol; 2007 Nov; 60(6):799-809. PubMed ID: 17285315
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics of total and unbound plasma cisplatin in adult patients.
Urien S; Lokiec F
Br J Clin Pharmacol; 2004 Jun; 57(6):756-63. PubMed ID: 15151521
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics of raltitrexed in patients with advanced solid tumours.
Blair EY; Rivory LP; Clarke SJ; McLachlan AJ
Br J Clin Pharmacol; 2004 Apr; 57(4):416-26. PubMed ID: 15025739
[TBL] [Abstract][Full Text] [Related]
13. [Validation of a new interactive software monitoring a controlled-flow infusion pump for cisplatin dosage regimen adjustment].
Cupissol D; Brès J; Gestin-Boyer C; Nouguier-Soulé J; Vian L; Tep A; Nouguier J
Bull Cancer; 1996 Aug; 83(8):664-76. PubMed ID: 8869047
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics and pharmacodynamics of cisplatinum during hyperthermic intraperitoneal chemotherapy using a closed abdominal procedure.
Cotte E; Colomban O; Guitton J; Tranchand B; Bakrin N; Gilly FN; Glehen O; Tod M
J Clin Pharmacol; 2011 Jan; 51(1):9-18. PubMed ID: 20173087
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetic/pharmacodynamic modeling for the time course of tumor shrinkage by motesanib in thyroid cancer patients.
Lu JF; Claret L; Sutjandra L; Kuchimanchi M; Melara R; Bruno R; Sun YN
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1151-8. PubMed ID: 20872145
[TBL] [Abstract][Full Text] [Related]
16. Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin.
Meerum Terwogt JM; Groenewegen G; Pluim D; Maliepaard M; Tibben MM; Huisman A; ten Bokkel Huinink WW; Schot M; Welbank H; Voest EE; Beijnen JH; Schellens JM
Cancer Chemother Pharmacol; 2002 Mar; 49(3):201-10. PubMed ID: 11935212
[TBL] [Abstract][Full Text] [Related]
17. A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling.
van den Bongard HJ; Mathôt RA; van Tellingen O; Schellens JH; Beijnen JH
Cancer Chemother Pharmacol; 2002 Jul; 50(1):16-24. PubMed ID: 12111107
[TBL] [Abstract][Full Text] [Related]
18. Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours.
Trocòniz IF; Garrido MJ; Segura C; Cendrós JM; Principe P; Peraire C; Obach R
Cancer Chemother Pharmacol; 2006 Jun; 57(6):727-35. PubMed ID: 16261364
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic drug monitoring for dose individualization of Cisplatin in testicular cancer patients based upon total platinum measurement in plasma.
Salas S; Mercier C; Ciccolini J; Pourroy B; Fanciullino R; Tranchand B; Monjanel-Mouterde S; Baciuchka-Palmaro M; Dupuis C; Yang C; Balti M; Lacarelle B; Duffaud F; Durand A; Favre R
Ther Drug Monit; 2006 Aug; 28(4):532-9. PubMed ID: 16885721
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics of melphalan, infused over a 24-hour period, in patients with advanced malignancies.
Mougenot P; Pinguet F; Fabbro M; Culine S; Poujol S; Astre C; Bressolle F
Cancer Chemother Pharmacol; 2004 Jun; 53(6):503-12. PubMed ID: 15007638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
